SCHEMBL4523501

SCHEMBL4523501

NC(=O)c1coc([CH]c2ccccc2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 4/20 0.44
MAPT P10636 3/20 0.44
CYP2C19 P33261 2/20 0.44
HSD17B10 Q99714 2/20 0.44
POLB P06746 1/20 0.44
CYP3A4 P08684 1/20 0.44
TSHR P16473 1/20 0.44
RECQL P46063 1/20 0.44
BLM P54132 1/20 0.44
PMP22 Q01453 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 2/20 0.38
LMNA P02545 2/20 0.38
HPGD P15428 2/20 0.38
DHODH Q02127 2/20 0.37
PLA2G10 O15496 1/20 0.36
PLA2G2A P14555 1/20 0.36
PARP10 Q53GL7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10177678 0.72 CYP2C19 (0.50) PARP1MAPTCYP2C19HSD17B10POLB
SCHEMBL4523133 0.69 HDAC4 (0.49) PARP1MAPTCYP2C19HSD17B10POLB
SCHEMBL4522155 0.68 SLC9A1 (0.40) PARP1MAPTCYP2C19HSD17B10POLB
SCHEMBL23188993 0.67 PLA2G2A (0.56) PARP1MAPTCYP2C19HSD17B10POLB
Benzamide SCHEMBL11447237 0.65 MAPT (0.70) PARP1MAPTCYP2C19HSD17B10POLB
SCHEMBL4156173 0.65 MAPT (0.62) PARP1MAPTCYP2C19HSD17B10POLB
SCHEMBL7187617 0.65 MAPT (0.62) PARP1MAPTCYP2C19HSD17B10POLB
SCHEMBL16131295 0.65 MAPT (0.62) PARP1MAPTCYP2C19HSD17B10POLB
SCHEMBL176636 0.65 MAPT (0.48) PARP1MAPTCYP2C19HSD17B10POLB
Benzamide SCHEMBL1222101 0.64 PARP1 (1.00) PARP1MAPTCYP2C19HSD17B10POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054445-A1 Amide Substituted Quinolines ASTRAZENECA AB (SE) 2009-02-26 US claimed
EP-1981882-A1 AMIDE SUBSTITUTED QUINOLINES AstraZeneca AB (SE) 2008-10-22 EP claimed
WO-2007086799-A1 AMIDE SUBSTITUTED QUINOLINES ASTRAZENECA AB (SE) 2007-08-02 WO claimed
US-20090054445-A1 Amide Substituted Quinolines ASTRAZENECA AB (SE) 2009-02-26 US disclosed
EP-1981882-A1 AMIDE SUBSTITUTED QUINOLINES AstraZeneca AB (SE) 2008-10-22 EP disclosed
WO-2007086799-A1 AMIDE SUBSTITUTED QUINOLINES ASTRAZENECA AB (SE) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054445-A1 Amide Substituted Quinolines RECQL, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-0 PARP1 1212/4885MAPT 2929/4885CYP2C19 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.